Revance Therapeutics, Inc.
RVNC · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $744 | $1,342 | $1,102 | $1,644 |
| - Cash | $137 | $109 | $111 | $334 |
| + Debt | $478 | $418 | $325 | $212 |
| Enterprise Value | $1,085 | $1,652 | $1,316 | $1,523 |
| Revenue | $234 | $133 | $78 | $15 |
| % Growth | 76.5% | 70.4% | 407.7% | – |
| Gross Profit | $82 | $81 | $54 | $11 |
| % Margin | 35% | 61% | 69.9% | 68.9% |
| EBITDA | -$291 | -$306 | -$255 | -$259 |
| % Margin | -124.2% | -230.5% | -328% | -1,692.1% |
| Net Income | -$324 | -$356 | -$287 | -$282 |
| % Margin | -138.4% | -268.9% | -368.7% | -1,840.7% |
| EPS Diluted | -3.83 | -4.9 | -4.25 | -4.86 |
| % Growth | 21.8% | -15.3% | 12.6% | – |
| Operating Cash Flow | -$217 | -$194 | -$222 | -$179 |
| Capital Expenditures | -$7 | -$23 | -$18 | -$4 |
| Free Cash Flow | -$223 | -$217 | -$240 | -$183 |